139 related articles for article (PubMed ID: 14978663)
1. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
[TBL] [Abstract][Full Text] [Related]
2. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
[TBL] [Abstract][Full Text] [Related]
3. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
4. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
Khanna D; Furst DE; Hays RD; Park GS; Wong WK; Seibold JR; Mayes MD; White B; Wigley FF; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally EV; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
[TBL] [Abstract][Full Text] [Related]
5. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
[TBL] [Abstract][Full Text] [Related]
6. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
7. D-penicillamine is not an effective treatment in systemic sclerosis.
Furst DE; Clements PJ
Scand J Rheumatol; 2001; 30(4):189-91. PubMed ID: 11578010
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
9. D-penicillamine in systemic sclerosis? Yes!
Medsger TA; Lucas M; Wildy KS; Baker C
Scand J Rheumatol; 2001; 30(4):192-4. PubMed ID: 11578011
[TBL] [Abstract][Full Text] [Related]
10. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
11. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
12. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
[TBL] [Abstract][Full Text] [Related]
13. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
Furst DE; Clements PJ; Wong WK; Mayes MD; Wigley F; White B; Weisman M; Barr W; Moreland L; Martin R; Medsger TA; Steen V; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Peter JB; Seibold JR
Rheumatology (Oxford); 2001 Jun; 40(6):615-22. PubMed ID: 11426017
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
15. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
Strand V
Arthritis Rheum; 2002 Nov; 46(11):2836-7. PubMed ID: 12428222
[No Abstract] [Full Text] [Related]
16. Penicillamine in the treatment of systemic sclerosis.
Clements PJ
Curr Rheumatol Rep; 1999 Oct; 1(1):38-42. PubMed ID: 11123013
[TBL] [Abstract][Full Text] [Related]
17. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.
Steen VD; Medsger TA; Rodnan GP
Ann Intern Med; 1982 Nov; 97(5):652-9. PubMed ID: 7137731
[TBL] [Abstract][Full Text] [Related]
18. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.
Derk CT; Huaman G; Jimenez SA
Br J Dermatol; 2008 May; 158(5):1063-8. PubMed ID: 18284395
[TBL] [Abstract][Full Text] [Related]
19. Dermal elastin and collagen in systemic sclerosis. Effect of D-penicillamine treatment.
Pasquali Ronchetti I; Guerra D; Quaglino D; Vincenzi D; Manzini E; Canossi B; Manzini CU
Clin Exp Rheumatol; 1989; 7(4):373-83. PubMed ID: 2591110
[TBL] [Abstract][Full Text] [Related]
20. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
